Shapiro Appointed Chair-Elect for ASCO Survivorship Committee

June 10, 2013

COLUMBUS, Ohio – Dr. Charles Shapiro, director of breast medical oncology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Reseach Institute (OSUCCC­–James) has been appointed to serve as Chair-Elect for the Survivorship Committee of the American Society of Clinical Oncology (ASCO). The appointment is effective this month. Shapiro will serve as Chair-Elect for one year, followed by a one year term as Chair. He will then serve as Immediate Past Chair.

Shapiro, who came to Ohio State in 1998 and is a professor of internal medicine, leads the breast cancer research program at Ohio State’s Comprehensive Cancer Center. He leads an interdisciplinary team of clinical and research scientists whose sole focus is the study of breast cancer.

Shapiro is a nationally known clinical investigator whose research interests include the development of novel treatments for breast cancer and treatment-related side effects of breast cancer, in particular the side effects of adjuvant chemotherapy in young women. He is currently overseeing major clinical trial and laboratory research efforts to develop new therapies that are effective for ‘triple negative’ breast cancer.

Shapiro serves as the vice chair of the Symptom Intervention Committee of the Alliance Cooperative Group, is a member of the Alliance Breast Committee, and a member of the NCI Symptom Management and Health-Related Quality of Life Steering Committee. He has been named among “America’s Top Doctors for Cancer,” “America’s Top Doctors” and “Best Doctors in America.”

He previously co-chaired ASCO’s task force on survivorship guidelines.

The Cancer Survivorship Committee provides leadership and oversight of ASCO’s cancer survivorship activities and assists in the implementation of the cancer survivorship components within ASCO’s mission and strategic plan. The committee reviews and assesses ASCO’s cancer survivorship portfolio and works to enhance the quality and quantity of cancer survivorship material in each program.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 228-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report.

# # #

Click here for a high-quality photo of Dr. Charles Shapiro

Contact: Alexis Shaw, Wexner Medical Center Public Affairs and Media Relations, 614-293-3737 or

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)

Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.


If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Ohio State, ORIEN Could Play Role in Vice President's Cancer Moonshot Initiative

ORIEN, a network formed by Ohio State and Moffitt Cancer Center, could play an important role in the White House Cancer Moonshot initiative by facilitating the sharing of important data.

Ohio State: An Exceptional Comprehensive Cancer Center Helping Cancer Patients

Director of the OSUCCC Dr. Michael Caligiuri discusses the importance of being an NCI-designated comprehensive cancer center, where research flourishes and the best scientists and physicians want to work.

A Fireside Chat with The James CEO Dr. Michael Caligiuri

Dr. Caligiuri hosts a chat where he talked about the “exceptional” rating The James recently received from the NCI, advances in immunology & how ORIEN could play a role in the cancer “moonshot” program.